Administer by deep subcutaneous injection into the abdominal wall, alternating sides. Do not inject intramuscularly. The air bubble in the syringe should not be expelled before injection to ensure full dose delivery. Do not mix with other injections.

Enoxaparin potentiates the activity of antithrombin III, leading to the inactivation of clotting factors, particularly Factor Xa and, to a lesser extent, Factor IIa (thrombin). This prevents the formation and growth of blood clots.

• •Active major bleeding or conditions with a high risk of uncontrolled bleeding (e.g., active gastric ulcer, hemorrhagic stroke).
• •History of heparin-induced thrombocytopenia (HIT) with or without thrombosis.
• •Hypersensitivity to enoxaparin, heparin, other low molecular weight heparins, or pork products.
• •Acute bacterial endocarditis.
• •Spinal or epidural anesthesia in patients with severe bleeding risk or within 24 hours of an enoxaparin dose for prophylaxis.

Store below 25°C (77°F). Do not freeze. Protect from light. Keep out of reach of children. Do not use if the solution is discolored or contains particles.

Accidental overdose can lead to hemorrhagic complications. The anticoagulant effects can be largely neutralized by the slow intravenous injection of protamine sulfate. Dose of protamine sulfate should be carefully adjusted based on the enoxaparin dose administered and time since administration.

Pregnancy: Category B. Limited human data suggest no increased risk of major birth defects. Use during pregnancy only if clearly needed. Lactation: Enoxaparin is excreted into breast milk in small amounts. Generally considered compatible with breastfeeding, but caution is advised.